Latest SEC filings for bioAffinity Technologies, Inc. (BIAF) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-15.
An 8-K reports a material event in the window between scheduled reports. There are 19 in this period for bioAffinity Technologies, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.
Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.
bioAffinity Technologies, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.
bioAffinity Technologies, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.
bioAffinity Technologies, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.
bioAffinity Technologies, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.
bioAffinity Technologies, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.
bioAffinity Technologies, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.
bioAffinity Technologies, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.
bioAffinity Technologies, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.
bioAffinity Technologies, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.
bioAffinity Technologies, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.
bioAffinity Technologies, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.
bioAffinity Technologies, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.
bioAffinity Technologies, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.
bioAffinity Technologies, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.
bioAffinity Technologies, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.
bioAffinity Technologies, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.
bioAffinity Technologies, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.
bioAffinity Technologies, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.
bioAffinity Technologies, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.
The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for bioAffinity Technologies, Inc.
The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.
An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.
bioAffinity Technologies, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.
Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.
The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.
Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.
A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on BIAF. Read these alongside the fundamentals rather than in isolation.
View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the BIAF stock analysis page.